Bullish & Foolish
Full HOWL fundamentals All 466 on the Survival Watch

HOWLWEREWOLF THERAPEUTICS, INC.

Is Werewolf Therapeutics struggling financially?

Yes, by its own account. Werewolf Therapeutics told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$42.5M
Source filing
10-Q 7 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 3months

    If the burn speeds up

    Empty by Sep 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$22.0M

÷

Cash burned over the last 12 months

$60.3M

What Werewolf Therapeutics told the SEC

…more fully in Part II, Item 1A. “Risk Factors” in this Quarterly Report. These risks include, but are not limited to, the following: We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report. We are currently evaluating strategies to raise…

WEREWOLF THERAPEUTICS, INC., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 45% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt